3. Frey KA, Koeppe RA, Kilbourn MR. Imaging the vesicular monoamine transporter. *Adv Neurol.* 2001;86:237–247.
4. Glenn AL, Raine A, Yaralian PS, Yang Y. Increased volume of the striatum in psychopathic individuals. *Biol Psychiatry.* 2010;67:52–58.
5. Gerfen CR. The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. *Annu Rev Neurosci.* 1992;15:285–320.
6. Kin T, Murdoch TB, Shapiro AM, Lakey JR. Estimation of pancreas weight from donor variables. *Cell Transplant.* 2006;15:181–185.
7. Watanabe T, Yaegashi H, Koizumi M, Toyota T, Takahashi T. Changing distribution of islets in the developing human pancreas: a computer-assisted three-dimensional reconstruction study. *Pancreas.* 1999;18:349–354.
8. Kung MP, Hou C, Lieberman BP, et al. In vivo imaging of beta-cell mass in rats using ^{18}F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus. *J Nucl Med.* 2008;49:1171–1176.
9. Kilbourn M, Lee L, Vander BT, Jewett D, Frey K. Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. *Eur J Pharmacol.* 1995;278:249–252.
10. Ichise M, Slifstein M, Easwaramoorthy B, et al. VMAT2 imaging of baboons with two ^{18}F-FP-DTBZ enantiomers [abstract]. *J Nucl Med.* 2009;50(suppl):227P.
11. Toyama H, Ichise M, Liow JS, et al. Absolute quantification of regional cerebral glucose utilization in mice by ^{18}F-FDG small animal PET scanning and 2-^{14}C-DG autoradiography. *J Nucl Med.* 2004;45:1398–1405.
12. Witkowski P, Sondermeijer H, Hardy MA, et al. Islet grafting and imaging in a bioengineered intramuscular space. *Transplantation.* 2009;88:1065–1074.

Masanori Ichise*
Paul E. Harris
**Columbia University Medical Center*
Hatch Center-NI B04L
710 W. 168th St
New York, NY 11032
E-mail: mi2193@columbia.edu

DOI: 10.2967/jnumed.110.086249

Errata

In the article "Assessment of Tumoricidal Efficacy and Response to Treatment with ^{18}F-FDG PET/CT After Intraarterial Infusion with the Antiglycolytic Agent 3-Bromopyruvate in the VX2 Model of Liver Tumor," by Liapi et al. (*J Nucl Med*. 2011;52:225–230), an acknowledgment of support from the Abdulrahman A. Abdulmalik Research Fund was inadvertently omitted. The authors regret the omission.

In the article "SNM Practice Guideline for Sodium ^{18}F-Fluoride PET/CT Bone Scans 1.0," by Segall et al. (*J Nucl Med.* 2010;51:1813–1820), the first paragraph of Section III, Definitions, incorrectly states that no applications for an Investigational New Drug have been filed with the U.S. Food and Drug Administration for ^{18}F. The corrected paragraph is shown below. The authors regret the error.

^{18}F is a diagnostic molecular imaging agent used for identification of new bone formation. ^{18}F, administered as intravenous Na^{18}F, was approved by the U.S. Food and Drug Administration in 1972 but has been listed as a discontinued drug since 1984. In 2000, the Food and Drug Administration listed it in the Orange Book for discontinued drug products. The original approval in 1972 may be used as a basis to reapply for marketing approval via a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA). Several clinical trials are currently using Na^{18}F with Investigational New Drug exemptions. In December 2008, the National Cancer Institute filed an NDA for a different potency and dose from the original NDA. Presently, Na^{18}F is manufactured and distributed for clinical use by authorized user prescription under state laws of pharmacy. In December 2011, Na^{18}F for clinical use will have to be prepared under an NDA or ANDA and meet the cGMP requirements of 21 CFR 212.